Background/Aims: Nuclear localization leucine-rich-repeat protein 1 (NLRP1) is a cytoplasmic protein, involved in autoimmune diseases, mammalian reproduction, neuronal cell death, and stroke. However, the role of NLRP1 in cardiac hypertrophy remains unclear. We used in vivo and in vitro models to investigate the effects of NLRP1 on cardiac hypertrophy. Methods: We used NLRP1-deficient mice and cultured neonatal rat cardiomyocytes with gain and loss of NLRP1 function. Cardiac hypertrophy was estimated by echocardiographic and hemodynamic measurements, and by pathological and molecular analysis. Results: Eight weeks after aortic banding (AB), NLRP1 deficiency significantly inhibited aortic banding-induced cardiac hypertrophy, inflammation, and fibrosis. Activation of MAPK, NF-κB, and TGF-β/Smad pathways was reduced in NLRP1-knockout (KO) mice compared with that in wild-type (WT) mice. Consistent with these results, in vitro studies, performed using cultured neonatal mouse cardiomyocytes, confirmed that NLRP1 deficiency protects against cardiomyocyte hypertrophy induced by isoproterenol (PE); this protective activity was associated with the arrest of MAPK and NF-κB signaling. Conclusions: Our data illustrates that NLRP1 plays a crucial role in the development of cardiac hypertrophy via positive regulation of the MAPK, NF-κB, and TGF-β/ Smad signaling pathways.
Introduction
Cardiovascular disease is a major cause of death worldwide. Approximately 17 million people die of cardiovascular disease each year [1] . In China, the incidence of cardiovascular disease has increased gradually. Heart failure, the world's fastest-growing cardiovascular
Echocardiography and hemodynamics
Echocardiography was performed by Mylab30CV (ESAOTE S.P.A) with a 10 MHz linear array ultrasound transducer. The left ventricle (LV) was assessed in both parasternal long-axis and short-axis views at a frame rate of 50 Hz. End-systole and end-diastole were defined as the phase in which the smallest or largest area of LV was obtained, respectively. The left ventricular end-diastolic diameter (LVEDD) and left ventricular end-systolic diameter (LVESD) were measured using the LV M-mode tracing with a sweep speed of 50 mm/s at the mid-papillary muscle level.
For hemodynamic measurements, mice were anesthetized with 1.5% isoflurane. A microtip catheter transducer (SPR-839, Millar Instruments, Houston, TX, USA) was inserted into the right carotid artery and advanced into the left ventricle. The pressure signals and heart rate were recorded continuously with a Millar Pressure-Volume System (MPVS-400, Millar Instruments, Houston, TX, USA), and the data were processed by PVAN data analysis software.
Histological analysis
Hearts were excised, washed with saline solution, and placed in 10% formalin. Hearts were cut transversely close to the apex to visualize the left and right ventricles. Several sections of the heart (4-5 μm thick) were prepared and stained with hematoxylin and eosin (H&E) for histopathology, or with picrosirius red (PSR) for collagen deposition, and visualized by light microscopy. To examine the myocyte cross-sectional area, membranes in the sections were stained with FITC-conjugated wheat germ agglutinin (WGA; Invitrogen) and nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI). A single myocyte was measured with a digital quantitative image digital analysis system (Image Pro-Plus, version 6.0). The outline of 100 myocytes was traced in each group.
Cultured neonatal rat cardiac myocytes and treatment with recombinant adenoviral vectors
Neonatal rat cardiomyocytes (NRCMs) were prepared as previously described [18] . Briefly, 1 to 2-dayold Sprague-Dawley rats were euthanized and the neonatal hearts were removed from the thoracic cavities. The heart tissues were finely minced and digested in phosphate buffered saline (PBS) containing 0.03% trypsin and 0.04% collagenase type II. After removing fibroblasts using a differential attachment technique, NRCMs were seeded at a density of 1×10 6 cells/well onto gelatin-coated six-well culture plates. A medium, consisting of DMEM/F12 supplemented with 20% fetal calf serum (FCS), BrdU (0.1 mM, used to inhibit the proliferation of fibroblasts), and penicillin/streptomycin was then added to these six-well plates. After 48 hours, the culture medium was replaced with serum-free DMEM/F12 for 12 hours prior to stimulation with phenylephrine (PE, 10 µM).
Replication-defective adenoviral vectors were used to overexpress rat NLRP1 (Ad-NLRP1) under the control of a cytomegalovirus promoter. A similar adenoviral vector, expressing green fluorescent protein (Ad-GFP), was used as a control. The rat Ad-shNLRP1 was used to knock down the expression of NLRP1, and Ad-shRNA was used as the nontargeting control. The neonatal rat cardiomyocytes were infected for 8 hours with Ad-GFP, Ad-NLRP1, Ad-shRNA, and Ad-shNLRP1 in diluted media at a multiplicity of infection (MOI) of 100.
To identify the role of NLRP1 in cardiac hypertrophy, we treated Ad-shRNA-infected, Ad-shNLRP1-infected, Ad-GFP-infected, and Ad-NLRP1-infected cardiomyocytes with isoproterenol (PE, 10 µM) for 24 hours.
Immunofluorescence
NRCMs were infected with different adenoviruses for 24 hours and then permeabilized with 0.1% Triton X-100 in PBS for 50 minutes. To determine the cell-surface areas, NRCMs were then labeled with α-actinin (Abcam, ab68194, 1:200 dilution) and cardiac troponin T (Abcam, ab8295, 1:100 dilution). NRCMs were then reacted with a FITC-labeled goat anti-rabbit secondary antibody (Aspen, AS-1110, 1:50 dilution) and a Cy3-labeled goat anti-mouse secondary antibody (Aspen, AS-1111, 1:50 dilution).
Quantitative real-time PCR.
Real-time PCR was used to detect RNA expression levels of hypertrophic and fibrotic markers. Total RNA was extracted from frozen, pulverized mouse cardiac tissue using TRIzol (Roche). cDNA was synthesized using oligo(dT) primers with an Advantage RT-for-PCR kit (Roche 
Western blotting
Mouse ventricles and cultured neonatal rat cardiac myocytes from the different groups were lysed in RIPA lysis buffer. Fifty micrograms of cell lysate was used for SDS/PAGE, and proteins were subsequently transferred to an Immobilon-P membrane (Millipore, Beijing, China). The specific protein expression levels were normalized to that of GAPDH for total cell lysates and cytosolic proteins on the same polyvinylidene difluoride membrane. The primary antibodies were specific for: Protein extracts (40 µg) of the myocardia from different groups were fractionated on a 10% SDS-PAGE (ASPEN, AS1012) and transferred to PVDF membranes (Millipore, IPVH00010). The membrane was blocked with 5% non-fat milk for 1 hour and incubated with the primary antibody at 4°C overnight. , and GAPDH (Abcam, ab37168). The membrane was then incubated with HRP-conjugated secondary antibody (ASPEN, AS1107) at 1:10000 dilutions for 1 hour at room temperature. After application of a chemiluminescence reagent, membranes were exposed to X-ray films.
Statistical analysis
Data are expressed as the means ± SEM. Differences among groups were assessed by two-way ANOVA followed by a post hoc Tukey's test. Comparisons between two groups were performed by unpaired Student's t-test. P<0.05 was considered statistically significant.
Results

NLRP1 expression in mouse cardiac hypertrophy induced by pressure overload
To explore the potential role of NLRP1 in cardiac hypertrophy, we investigated the expression of NLRP1 in response to hypertrophic stresses in mice. The expression levels of the NLRP1 protein were elevated for 1 to 8 weeks after AB. The levels of hypertrophic makers, such as atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP), and β-myosin heavy chain (β-MHC), were higher in WT mice for 1 to 8 weeks after AB (Fig. 1 ). This indicates that the expression and activity of NLRP1 were enhanced in response to hypertrophic stimuli, and that NLRP1 may participate in cardiac hypertrophy.
NLRP1 deficiency alleviates cardiac hypertrophy and dysfunction induced by AB
To determine how the absence of NLRP1 affects the hypertrophic response to pressure overload, we used NLRP1 KO mice and WT littermates (Fig. 2a) ; both groups of mice were subjected to AB or a sham procedure. After 8 weeks, we assessed the cardiac function of KO and WT mice by echocardiography and pressure-volume (PV) loop. The increases in the dimensions of the LV chamber and interventricular septal thickness, induced by pressure overload, were significantly attenuated during both the systole and diastole in KO mice Table 1 ). NLRP1 KO mice showed attenuated cardiac hypertrophy 8 weeks after AB. These mice had decreased ratios of heart weight/body weight (HW/BW), lung weight/body weight (LW/BW), and heart weight/tibia length (HW/TL) ( Fig.  2b) , as assessed by the morphology of the gross heart, H&E staining, WGA staining, and cardiomyocyte cross-sectional area (Fig. 2c) . The levels of hypertrophic markers, including ANP, BNP, and β-MHC, were reduced in the KO mice after pressure overload. This was accompanied by the upregulation of α-myosin heavy chain (α-MHC) and sarcoendoplasmic reticulum Ca 2+ -ATPase (SERCA2a) (Fig. 2d) . These results indicate that ablation of NLRP1 abates cardiac hypertrophy and blocks impaired cardiac function after pressure overload.
NLRP1 deficiency represses cardiomyocyte hypertrophy in vitro
To further examine the effect of NLPR1 on cardiac hypertrophy, we treated cultured neonatal rat cardiomyocytes with PE (10 µM). The cells were infected with Ad-GFP, Ad-NLRP1, Ad-shRNA, or Ad-shNLRP1 for 24 hours, then serum starved for 24 hours in 0.5% FCS. The cells then were exposed to either PE (10 µM) or a PBS control for 24 hours (Fig. 3a) . After stimulation with PE, the expression of NLRP1 was downregulated by infection with Ad-shNLRP1. This inhibited cell hypertrophy and mRNA expression of ANP, BNP, and β-MHC compared with those in the negative control (Ad-shRNA) group (Fig. 3b, d) . Conversely, overexpression of NLRP1, induced via infection with Ad-NLRP1, promoted cell hypertrophy and mRNA expression of ANP, BNP, and β-MHC (Fig. 3c, e) . These findings indicate that NLRP1 deficiency blocks cardiac hypertrophy in vitro.
Effects of NLRP1 on MAPK signaling
To explore the molecular mechanisms of NLRP1 in cardiac hypertrophy, we investigated the activation of mitogen-activated protein kinase (MAPK) pathway in KO and WT hearts in response to pressure overload. The levels of phosphorylated JNK1/2, p38, and ERK1/2 were significantly increased in the mice after AB. However, this increased phosphorylation of JNK1/2, p38, and ERK1/2 was blocked in NLRP1-deficient hearts (Fig. 4a) . Consistent with the results of our in vivo procedures, the activation of JNK1/2, p38, and ERK1/2 was markedly reduced in Ad-shNLRP1 cardiomyocytes compared with that of control cells after treatment with PE. In contrast, the levels of phosphorylated JNK1/2, p38, and ERK1/2 were upregulated in Ad-NLRP1 cardiomyocytes (Fig. 4b, c) . These results indicate that MAPK signaling was vital for the effects of NLRP1 on cardiac hypertrophy. 
NLRP1 ablation weakens cardiac inflammation
Activation of inflammatory cytokines and NF-κB signaling mediate the development and progression of cardiac hypertrophy [19] . We examined the mRNA expression of NF-κB target genes, including interleukin (IL)-1β, IL-6, and tumor necrosis factor (TNF)-α, in the cardiac tissue of KO mice and their WT littermates 8 weeks after AB (Fig. 5a ). The phosphorylation of IKKβ, IkBα, and NF-kBp65 was significantly reduced, whereas the total level of IkBα was higher post AB in KO mice compared with that in WT mice (Fig. 5b) . Consistent with the results of our in vivo procedure, the mRNA expressions of IL-1β, IL-6, and TNF-α was reduced in Ad-shNLRP1 cardiomyocytes compared with that of control cells after treatment with PE. In contrast, the mRNA expressions of IL-1β, IL-6, and TNF-α was upregulated in Ad-NLRP1 cardiomyocytes (Fig. 5c) . Compared with the levels observed in control cells, the phosphorylation of IKKβ, IkBα, and NF-kBp65 was significantly inhibited, whereas the total level of IkBα was higher, in Ad-shNLRP1 cardiomyocytes after treatment with PE. The 
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phosphorylation of IKKβ, IkBα, and NF-kBp65 was significantly increased, whereas the total level of IkBα was lower, in Ad-NLRP1 cardiomyocytes after treatment with PE (Fig. 5d) .
NLRP1 ablation attenuates cardiac fibrosis induced by pressure overload
Cardiac fibrosis is a characteristic feature of pathological cardiac hypertrophy. To further illustrate the mechanism by which NLRP1 ablation inhibits cardiac hypertrophy, heart sections were stained with PSR to detect left ventricular interstitial fibrosis. Perivascular and interstitial fibrosis, and LV collagen volume, were significantly increased in WT mice subjected to AB; however, cardiac fibrosis was markedly attenuated in KO mice compared with that in their WT littermates. Left ventricular interstitial fibrosis was evaluated by PSR conducted using paraffin-embedded sections. Perivascular and interstitial fibrosis was detected in both KO and WT mice, but the extent of cardiac fibrosis was markedly inhibited in KO mice (Fig. 6a, b) . Moreover, the mRNA expression levels of known mediators of fibrosis, including collagen I, collagen III, and connective tissue growth factor (CTGF), were remarkably downregulated in KO mice compared with the levels in WT mice after treatment with AB (Fig. 6c) . To further investigate whether NLRP1 deficiency can inhibit fibrosis, we assessed the regulatory role of NLRP1 in the activation of the TGF-β/Smad cascade. The protein-expression levels of TGF-β, TGF-βR I, TGF-βR II, p-Smad2, p-Smad3, and Smad4 were decreased in KO mice after AB (Fig. 6d, e) . Collectively, these data suggest that NLRP1 deficiency plays an anti-fibrotic role by blunting the TGF-β/Smad signaling.
Discussion
In this study, we used NLRP1 KO mice and neonatal rat cardiomyocytes infected with Ad-GFP, Ad-NLRP1, Ad-shRNA, and Ad-shNLRP1 to explore the role of NLRP1 in the hypertrophic response. Our results demonstrate that the ablation of NLRP1 protected against cardiac hypertrophy, inflammation, and fibrosis under conditions of pressure overload. The effects of NLRP1 on cardiac hypertrophy, inflammation, and fibrosis likely occur via regulation of the MAPK, NF-κB, and TGF-β/Smad signaling pathways. These results suggest that NLRP1 may play an aggravating role in pathological hypertrophy of the heart.
The NLR protein family is divided into several sub-families according to differences in the N-terminal domain [20] . Unlike humans, which have a single NLRP1 gene, the mouse NLRP1 gene has three homologues: Nlrp1a, Nlrp1b, and Nlrp1c [21] . NLRP1 mRNA is expressed in many tissues such as the heart, spleen, brain, lung, liver, kidney, and muscle [22] . The expression levels of the NLRP1 protein were observably upregulated at 1 to 8 weeks after AB in WT mice. The ablation of NLRP1 alleviated pathological cardiac hypertrophy and dysfunction in response to pressure overload. Numerous factors, such as Ang-II, PE, ET-1, catecholamines, growth factors, and TNF-α, can induce ventricular hypertrophy [23] [24] [25] . On the cellular level, the expression of the NLRP1 protein was higher after treatment with PE. Depletion of NLRP1 during treatment with PE led to the reduced size of cardiomyocyte. Cardiac hypertrophy is a common response to external stressors, including mechanical overload and neurohormonal stimulation. According to our data, ablation of NLRP1 attenuated cardiac hypertrophy induced by pressure overload and the phenylephrine-induced hypertrophic response in NRCMs; overexpression of NLRP1 promoted hypertrophy in NRCMs.
The MAPK cascade is a classical pathway involved in cardiac hypertrophy. MAPK signaling is initiated in cardiac myocytes by various stress stimuli. Once activated, downstream JNKs, p38, and ERKs phosphorylate a wide array of intracellular targets including numerous transcription factors; this results in the reprogramming of cardiac gene expression [19, 26, 27] . NOD-like receptors (NLRs), the major constituents of the cytosolic innate immunesensing machinery, participate in multiple pathways including NF-κB and MAPK pathways [28, 29] . A close relationship exists between inflammasome signaling and other signaling pathways (especially that involving TLR) [30] . The activity of inflammasome corpuscles requires a double signal stimulus. The first signal is referred to as a pre-stimulus signal, mediated by TLR or other pattern recognition receptors. [31] . According to our data, the protein levels of JNK1/2, p38, and ERK1/2 phosphorylation, in response to hypertrophic stimuli, were significantly increased in NLRP1-KO mice. Our in vitro studies show that inhibition of NLRP1 expression significantly decreased the activation of JNK1/2, p38, and ERK1/2, while overexpression of NLRP1 greatly enhanced the activation of JNK1/2, p38, and ERK1/2. These findings indicate that the inhibitory effects of NLRP1 ablation on cardiac hypertrophy are mediated by MAPK signaling.
Inflammation plays an important role in the pathological progress of cardiac hypertrophy [24] . Inflammatory signaling molecules, released during cardiac remodeling, can induce hypertrophic and fibrotic responses [32] . In cardiomyocytes, major proinflammatory cytokines, such as TNF-α, IL-1β, and IL-6 induce hypertrophy and promote inflammation [33, 34] . NF-κB is a dimeric transcription factor that is kept inactive in the cytoplasm by inhibitory κB proteins (i.e., IκBs). The IKK/NF-κB signaling pathway is an important regulator of inflammation. Activation of IKK/NF-κB is implicated in cardiac hypertrophy [35, 36] . In adult animals, activation of IKK2 (IKKβ) leads to inflammatory dilated cardiomyopathy and heart failure [36] . NLRs participate in NF-κB signaling [28, 37] . According to our results, NLRP1 significantly enhanced the activation of NF-κB by disrupting transcriptional activity. This occurred by promoting the phosphorylation of IKKβ and IκBα, and by enhancing the expression of NF-κB target genes (IL-1β, IL-10, and TNF-α) in hypertrophic hearts. Our in vitro studies showed that NLRP1 depletion in NRCMs attenuated the PE-mediated hypertrophic effects, while overexpression of NLRP1 aggravated NRCM hypertrophy in response to PE stimuli. Mechanically, PE-induced activation of NF-κB inhibited in the NRCMs infected with Ad-shNLRP1; infection with Ad-NLRP1 increased NF-κB activation in NRCMs. These findings further confirm that ablation of NLRP1 protects cardiomyocytes against hypertrophy by decreasing the signaling of NF-κB.
Cardiac fibrosis induces pathological changes that culminate in chamber dilatation and cardiomyocyte hypertrophy. TGF-β is upregulated in the hypertrophied and fibrotic hearts, and is regarded as one of the major profibrotic cytokines and critical mediators of cardiac fibrosis [32] . The canonical pathway of TGF-β signaling is transduced through Smad and non-Smad pathways. The TGF-β ligand could bind to TGF-βR I and TGF-βR II. TGF-βR II phosphorylates TGF-βR I; then, they phosphorylate and activate Smad2 and Smad3, which bind Smad4 and translocate to the nucleus. The complex acts as a transcription factor, inducing the activation of numerous profibrotic genes [38] [39] [40] . In our study, the mRNA expression of collagen I, collagen III, and CTGF, which are responsible for cardiac fibrosis, was markedly downregulated in NLRP1-KO mice compared with the levels in WT mice in response to pressure overload. NLRP1 ablation abrogated the expression of TGF-β, TGF-βR I, and TGF-βR II, as well as phosphorylation of Smad2, Smad3, and Smad4 in the hypertrophied hearts, thus inhibiting fibrosis. Collectively, these data indicate that NLRP1 ablation attenuates fibrosis by blocking TGF-β/Smad signaling.
In conclusion, this study provides the first direct evidence that NLRP1 promotes cardiac hypertrophy, inflammation, and fibrosis in response to hypertrophic stimuli by activating the MAPK, NF-κB, and TGF-β/Smad signaling pathways. This study helps us understand the effects of NLRP1 on cardiac hypertrophy and the related molecular mechanisms. The potential of NLRP1 as a therapeutic target will be assessed in further studies.
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